Pharmacokinetic modulation of aspirin and acetaminophen

Pharmacokinetic modulation of aspirin and acetaminophen is not a biological target, such as a receptor or enzyme, but rather a description of the pharmacological interactions and metabolic processes governing these two drugs. Aspirin (acetylsalicylic acid) is a nonsteroidal anti-inflammatory drug (NSAID) that provides analgesic, antipyretic, and anti-inflammatory effects by covalently modifying cyclooxygenase enzymes (PubChem, 2024). Acetaminophen (paracetamol) is a widely used analgesic and antipyretic that is primarily metabolized in the liver through glucuronidation and sulfation, with a minor but significant pathway involving CYP2E1 which produces the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI) (StatPearls, 2023). The term refers to how these drugs may influence each other's absorption—for instance, through aspirin's effect on gastric mucosa and emptying—or compete for shared metabolic enzymes and clearance mechanisms (PubMed, PMID: 3055458). Because this entry describes a complex drug-drug interaction or a pharmacokinetic phenomenon rather than a specific molecular entity that can be targeted by a drug, it is considered an incorrect target designation in a therapeutic context. Understanding these modulations is essential for clinical safety, particularly to prevent additive toxicities such as hepatotoxicity or renal impairment when these agents are used in combination (FDA, 2022).

Other names

Aspirin-acetaminophen interactionASA-APAP pharmacokinetic interactionPharmacokinetic drug-drug interaction of analgesics

Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and COX-2 (PubChem CID 2244), while acetaminophen is thought to act via central COX inhibition and modulation of the endocannabinoid system (StatPearls, 2023). Pharmacokinetic modulation involves competition for hepatic metabolic pathways such as glucuronidation and sulfation, as well as aspirin-induced changes in gastric emptying that affect acetaminophen absorption rates.